A recent study has generated compelling experimental data on the role of GPR177 and WNT5a in the pathogenesis and treatment of painful diabetic neuropathy (PDN). The clinical value of these translational findings should be interpreted with caution. However, the limited efficacy of current treatments for PDN warrants further clinical studies on these novel pathways.

中文翻译：

---

疼痛性糖尿病神经病变疼痛的新机制

最近的一项研究产生了关于 GPR177 和 WNT5a 在疼痛性糖尿病神经病变 (PDN) 的发病机制和治疗中作用的令人信服的实验数据。应谨慎解释这些转化结果的临床价值。然而，目前治疗 PDN 的疗效有限，需要对这些新途径进行进一步的临床研究。